Tags

Type your tag names separated by a space and hit enter

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Mov Disord. 2007 Oct 15; 22(13):1860-5.MD

Abstract

We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint-the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score-was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off" was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.

Authors+Show Affiliations

Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan. y-Mizuno@med.juntendo.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17618525

Citation

Mizuno, Yoshikuni, et al. "Ropinirole Is Effective On Motor Function when Used as an Adjunct to Levodopa in Parkinson's Disease: STRONG Study." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 22, no. 13, 2007, pp. 1860-5.
Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mov Disord. 2007;22(13):1860-5.
Mizuno, Y., Abe, T., Hasegawa, K., Kuno, S., Kondo, T., Yamamoto, M., Nakashima, M., & Kanazawa, I. (2007). Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Movement Disorders : Official Journal of the Movement Disorder Society, 22(13), 1860-5.
Mizuno Y, et al. Ropinirole Is Effective On Motor Function when Used as an Adjunct to Levodopa in Parkinson's Disease: STRONG Study. Mov Disord. 2007 Oct 15;22(13):1860-5. PubMed PMID: 17618525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. AU - Mizuno,Yoshikuni, AU - Abe,Takashi, AU - Hasegawa,Kazuko, AU - Kuno,Sadako, AU - Kondo,Tomoyoshi, AU - Yamamoto,Mitsutoshi, AU - Nakashima,Mitsuyoshi, AU - Kanazawa,Ichiro, AU - ,, PY - 2007/7/10/pubmed PY - 2008/3/22/medline PY - 2007/7/10/entrez SP - 1860 EP - 5 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 22 IS - 13 N2 - We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint-the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score-was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off" was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/17618525/Ropinirole_is_effective_on_motor_function_when_used_as_an_adjunct_to_levodopa_in_Parkinson's_disease:_STRONG_study_ L2 - https://doi.org/10.1002/mds.21313 DB - PRIME DP - Unbound Medicine ER -